Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Rheumatoid arthritis is a painful, debilitating disease in which inflammation is localized mainly to synovial joints. Despite a plethora of therapies targeted at inflammatory cells such as lymphocytes, there has been little impact made on affecting a cure. Even with the most effective current treatments (antitumor necrosis factor-α agents), only about 50% of patients gain a 70% response as measured by conventional disease activity criteria (ARC 70). In recent years, stromal cells that define the microenvironment in which inflammation occurs have been shown to play an important role in the pathogenesis of rheumatoid arthritis, especially during the switch from acute to chronic persistent disease. In this review, the role that stromal cells, such as endothelial cells, fibroblasts and macrophages play in the pathogenesis of rheumatoid arthritis are examined, and it is suggested that these cells in addition to inflammatory immune cells provide an important and underappreciated therapeutic target. © 2005 Future Drugs Ltd.

Original publication

DOI

10.1586/14750708.2.1.121

Type

Journal article

Journal

Therapy

Publication Date

01/01/2005

Volume

2

Pages

121 - 129